Lu Y - Search Results

1

The Violence Prevention Potential of Reducing Alcohol Outlet Access in Baltimore, Maryland.

Trangenstein PJ, Eck RH, Lu Y, Webster D, Jennings JM, Latkin C, Milam AJ, Furr-Holden D, Jernigan DH. Trangenstein PJ, et al. Among authors: lu y. J Stud Alcohol Drugs. 2020 Jan;81(1):24-33. doi: 10.15288/jsad.2020.81.24. J Stud Alcohol Drugs. 2020. PMID: 32048598 Free PMC article.

2

CSF biomarker changes precede symptom onset of mild cognitive impairment.

Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, O'Brien R; BIOCARD Research Team. Moghekar A, et al. Among authors: lu y. Neurology. 2013 Nov 12;81(20):1753-8. doi: 10.1212/01.wnl.0000435558.98447.17. Epub 2013 Oct 16. Neurology. 2013. PMID: 24132375 Free PMC article.

3

Relationship of cognitive reserve and APOE status to the emergence of clinical symptoms in preclinical Alzheimer's disease.

Pettigrew C, Soldan A, Li S, Lu Y, Wang MC, Selnes OA, Moghekar A, O'Brien R, Albert M, The Biocard Research Team. Pettigrew C, et al. Among authors: lu y. Cogn Neurosci. 2013;4(3-4):136-42. doi: 10.1080/17588928.2013.831820. Epub 2013 Aug 25. Cogn Neurosci. 2013. PMID: 24168200 Free PMC article.

4

Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease.

Soldan A, Pettigrew C, Lu Y, Wang MC, Selnes O, Albert M, Brown T, Ratnanather JT, Younes L, Miller MI; BIOCARD Research Team. Soldan A, et al. Among authors: lu y. Hum Brain Mapp. 2015 Jul;36(7):2826-41. doi: 10.1002/hbm.22810. Epub 2015 Apr 16. Hum Brain Mapp. 2015. PMID: 25879865 Free PMC article.

5

Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype.

Albert M, Soldan A, Gottesman R, McKhann G, Sacktor N, Farrington L, Grega M, Turner R, Lu Y, Li S, Wang MC, Selnes O. Albert M, et al. Among authors: lu y. Curr Alzheimer Res. 2014;11(8):773-84. doi: 10.2174/156720501108140910121920. Curr Alzheimer Res. 2014. PMID: 25212916 Free PMC article.

6

The social amplification and attenuation of COVID-19 risk perception shaping mask wearing behavior: A longitudinal twitter analysis.

Hopfer S, Fields EJ, Lu Y, Ramakrishnan G, Grover T, Bai Q, Huang Y, Li C, Mark G. Hopfer S, et al. Among authors: lu y. PLoS One. 2021 Sep 23;16(9):e0257428. doi: 10.1371/journal.pone.0257428. eCollection 2021. PLoS One. 2021. PMID: 34555060

7

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.

Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, Diaz Avalos R, Zyla D, Buck T, Hui S, Shaffer K, Hariharan C, Yin J, Olmedillas E, Enriquez A, Parekh D, Abraha M, Feeney E, Horn GQ; CoVIC-DB team1, Aldon Y, Ali H, Aracic S, Cobb RR, Federman RS, Fernandez JM, Glanville J, Green R, Grigoryan G, Lujan Hernandez AG, Ho DD, Huang KA, Ingraham J, Jiang W, Kellam P, Kim C, Kim M, Kim HM, Kong C, Krebs SJ, Lan F, Lang G, Lee S, Leung CL, Liu J, Lu Y, MacCamy A, McGuire AT, Palser AL, Rabbitts TH, Rikhtegaran Tehrani Z, Sajadi MM, Sanders RW, Sato AK, Schweizer L, Seo J, Shen B, Snitselaar JJ, Stamatatos L, Tan Y, Tomic MT, van Gils MJ, Youssef S, Yu J, Yuan TZ, Zhang Q, Peters B, Tomaras GD, Germann T, Saphire EO. Hastie KM, et al. Among authors: lu y. Science. 2021 Sep 23:eabh2315. doi: 10.1126/science.abh2315. Online ahead of print. Science. 2021. PMID: 34554826

8

HTL-Free Sb₂(S, Se)₃ Solar Cells with an Optimal Detailed Balance Band Gap.

Lu Y, Li K, Yang X, Lu S, Li S, Zheng J, Fu L, Chen C, Tang J. Lu Y, et al. ACS Appl Mater Interfaces. 2021 Sep 23. doi: 10.1021/acsami.1c10758. Online ahead of print. ACS Appl Mater Interfaces. 2021. PMID: 34553903

9

Wearable, Washable, and Highly Sensitive Piezoresistive Pressure Sensor Based on a 3D Sponge Network for Real-Time Monitoring Human Body Activities.

Li X, Li X, Ting Liu, Lu Y, Shang C, Ding X, Zhang J, Feng Y, Xu FJ. Li X, et al. Among authors: lu y. ACS Appl Mater Interfaces. 2021 Sep 23. doi: 10.1021/acsami.1c09975. Online ahead of print. ACS Appl Mater Interfaces. 2021. PMID: 34553599

10

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.

Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, Rau KM, Sangai T, Ng TY, Tseng LM, Bryce R, Bebchuk J, Chen MC, Hou MF. Dai MS, et al. Among authors: lu ys. Breast Cancer Res Treat. 2021 Sep 23. doi: 10.1007/s10549-021-06313-5. Online ahead of print. Breast Cancer Res Treat. 2021. PMID: 34553296

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results